• Explore /
  • Poster
  • / A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Abstract Poster

Authors

null

Shukui Qin

People’s Liberation Army (PLA) 81 Hospital, Nanjing, China

Shukui Qin , Richard S. Finn , Masatoshi Kudo , Tim Meyer , Arndt Vogel , Michel Ducreux , Teresa Macarulla Mercade , Gianluca Tomasello , Frederic Boisserie , Jeannie Hou , Cindy Li , James Song , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03412773

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3110)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3110

Abstract #

TPS3110

Poster Bd #

319b

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Bruno Sangro

First Author: Richard S. Finn

First Author: Richard S. Finn